
## F Xavier Lopez-Labrador

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6894941/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Retrospective screening for SARSâ€CoVâ€2 among influenzaâ€like illness hospitalizations: 2018–2019 and 2019–2020 seasons, Valencia region, Spain. Influenza and Other Respiratory Viruses, 2022, 16, 166-171.	3.4	4
2	Cytomegalovirus specific polyfunctional T-cell responses expressing CD107a predict control of CMV infection after liver transplantation. Cellular Immunology, 2022, 371, 104455.	3.0	4
3	Role of age and birth month in infants hospitalized with RSV onfirmed disease in the Valencia Region, Spain. Influenza and Other Respiratory Viruses, 2022, 16, 328-339.	3.4	9
4	Effect of oral antiseptics in reducing SARS-CoV-2 infectivity: evidence from a randomized double-blind clinical trial. Emerging Microbes and Infections, 2022, 11, 1833-1842.	6.5	18
5	Recommendations for the introduction of metagenomic high-throughput sequencing in clinical virology, part I: Wet lab procedure. Journal of Clinical Virology, 2021, 134, 104691.	3.1	42
6	Influenza Vaccine Effectiveness and Waning Effect in Hospitalized Older Adults. Valencia Region, Spain, 2018/2019 Season. International Journal of Environmental Research and Public Health, 2021, 18, 1129.	2.6	4
7	Recommendations for the introduction of metagenomic next-generation sequencing in clinical virology, part II: bioinformatic analysis and reporting. Journal of Clinical Virology, 2021, 138, 104812.	3.1	39
8	Whole-Genome Analysis Surveillance of Influenza A Virus Resistance to Polymerase Complex Inhibitors in Eastern Spain from 2016 to 2019. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	4
9	Benchmark of thirteen bioinformatic pipelines for metagenomic virus diagnostics using datasets from clinical samples. Journal of Clinical Virology, 2021, 141, 104908.	3.1	28
10	Clinical evaluation of antiseptic mouth rinses to reduce salivary load of SARS-CoV-2. Scientific Reports, 2021, 11, 24392.	3.3	36
11	A European multicentre evaluation of detection and typing methods for human enteroviruses and parechoviruses using RNA transcripts. Journal of Medical Virology, 2020, 92, 1065-1074.	5.0	11
12	A population-based screening for hepatitis C antibodies and active infection using a point-of-care test in a low prevalence area. PLoS ONE, 2020, 15, e0228351.	2.5	11
13	Influenza vaccine effectiveness against laboratory-confirmed influenza in hospitalised adults aged 60 years or older, Valencia Region, Spain, 2017/18 influenza season. Eurosurveillance, 2019, 24, .	7.0	7
14	Recommendations for enterovirus diagnostics and characterisation within and beyond Europe. Journal of Clinical Virology, 2018, 101, 11-17.	3.1	161
15	Performance of the OraQuick Hepatitis C virus antibody test in oral fluid and fingerstick blood before and after treatment-induced viral clearance. Journal of Clinical Virology, 2018, 102, 77-83.	3.1	33
16	Influenza vaccine effectiveness in preventing hospitalisation of individuals 60 years of age and over with laboratory-confirmed influenza, Valencia Region, Spain, influenza season 2016/17. Eurosurveillance, 2018, 23, .	7.0	9
17	Waning protection of influenza vaccination during four influenza seasons, 2011/2012 to 2014/2015. Vaccine, 2017, 35, 5799-5807.	3.8	51
18	Low influenza vaccine effectiveness and the effect of previous vaccination in preventing admission with A(H1N1)pdm09 or B/Victoria-Lineage in patients 60 years old or older during the 2015/2016 influenza season. Vaccine, 2017, 35, 7331-7338.	3.8	18

#	Article	IF	CITATIONS
19	Genetic characterization of influenza viruses from influenza-related hospital admissions in the St. Petersburg and Valencia sites of the Global Influenza Hospital Surveillance Network during the 2013/14 influenza season. Journal of Clinical Virology, 2016, 84, 32-38.	3.1	7
20	Comprehensive Screening for Naturally Occurring Hepatitis C Virus Resistance to Direct-Acting Antivirals in the NS3, NS5A, and NS5B Genes in Worldwide Isolates of Viral Genotypes 1 to 6. Antimicrobial Agents and Chemotherapy, 2016, 60, 2402-2416.	3.2	52
21	Overcoming drug resistance in HSV, CMV, HBV and HCV infection. Future Microbiology, 2015, 10, 1759-1766.	2.0	5
22	Effectiveness of influenza vaccination programme in preventing hospital admissions, Valencia, 2014/15 early results. Eurosurveillance, 2015, 20, .	7.0	24
23	Hepatitis C virus genetic association to rate of liver fibrosis progression. , 2013, , .		2
24	Hepatitis C virus resistance to new specifically-targeted antiviral therapy: A public health perspective. World Journal of Virology, 2013, 2, 6.	2.9	19
25	New developments in the management of hepatitis C virus infection: focus on boceprevir. Biologics: Targets and Therapy, 2012, 6, 249.	3.2	2
26	Boceprevir in the treatment of chronic hepatitis C virus infection. Virus Adaptation and Treatment, 2011, , 7.	1.5	2
27	Recombination in Hepatitis C Virus. Viruses, 2011, 3, 2006-2024.	3.3	78
28	Relating the liver damage with hepatitis C virus polymorphism in core region and human variables in HIV-1-coinfected patients. Infection, Genetics and Evolution, 2010, 10, 1252-1261.	2.3	3
29	Clinical relevance of genetic heterogeneity in HCV. Future Virology, 2010, 5, 33-49.	1.8	6
30	Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates. Antiviral Therapy, 2008, 13, 481-94.	1.0	26
31	Mapping Natural Polymorphisms of Hepatitis C virus NS3/4A Protease and Antiviral Resistance to Inhibitors in Worldwide Isolates. Antiviral Therapy, 2008, 13, 481-494.	1.0	63
32	Trends for genetic variation of Hepatitis C Virus quasispecies in Human Immunodeficiency virus-1 coinfected patients. Virus Research, 2007, 130, 285-291.	2.2	15
33	Genetic variability of hepatitis C virus NS3 protein in human leukocyte antigen-A2 liver transplant recipients with recurrent hepatitis C. Liver Transplantation, 2004, 10, 217-227.	2.4	19
34	Genetic variability of hepatitis C virus non-structural protein 3 and virus-specific CD8+ response in patients with chronic hepatitis C. Journal of Medical Virology, 2004, 72, 575-585.	5.0	10
35	Hepatitis C and liver transplantation. Journal of Hepatology, 2001, 35, 666-678.	3.7	277
36	Quantitative analysis of hepatitis C virus-specific CD8+ T cells in peripheral blood and liver using peptide-MHC tetramers. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 5692-5697.	7.1	401

#	Article	IF	CITATIONS
37	Relationship of the genomic complexity of hepatitis C virus with liver disease severity and response to interferon in patients with chronic HCV genotype 1b interferon. Hepatology, 1999, 29, 897-903.	7.3	73
38	Comparative study of a modified competitive RT-PCR and amplicor HCV monitor assays for quantitation of hepatitis C virus RNA in serum. , 1999, 58, 35-43.		17
39	Prevalence and mother-to-infant transmission of hepatitis viruses B, C, and E in Southern Tanzania. , 1999, 58, 215-220.		91
40	The Prognostic Relevance of the Nonstructural 5A Gene Interferon Sensitivity Determining Region Is Different in Infections with Genotype 1b and 3a Isolates of Hepatitis C Virus. Journal of Infectious Diseases, 1998, 177, 839-847.	4.0	113
41	Hepatitis C virus (HCV) genotypes in Spanish patients with HCV infection: relationship between HCV genotype 1b, cirrhosis and hepatocellular carcinoma. Journal of Hepatology, 1997, 27, 959-965.	3.7	120